ValuEngine downgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a hold rating to a sell rating in a research report sent to investors on Thursday morning.

Separately, B. Riley reiterated a buy rating and issued a $20.00 target price on shares of Oramed Pharmaceuticals in a research note on Tuesday, January 16th.

Shares of ORMP stock opened at $7.38 on Thursday. Oramed Pharmaceuticals has a twelve month low of $6.15 and a twelve month high of $11.34.

A hedge fund recently raised its stake in Oramed Pharmaceuticals stock. Renaissance Technologies LLC lifted its holdings in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) by 12.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 93,500 shares of the biotechnology company’s stock after buying an additional 10,500 shares during the quarter. Renaissance Technologies LLC owned 0.65% of Oramed Pharmaceuticals worth $842,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 2.62% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Oramed Pharmaceuticals (ORMP) Downgraded by ValuEngine” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/04/22/oramed-pharmaceuticals-ormp-downgraded-by-valuengine.html.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.